C-TASC, a clinical trials solutions company, announced today that it will assist the FDA Centers for Quality Assurance and Biostatistics to develop new methods and procedures for evaluating all NDAs submitted for FDA approval.
FDA SElects c-tasc to improve review process
for new drug applications
StudyCTMSTM Will Be Used to Standardize How Clinical Trial Data is Presented and Reviewed for FDA Approval
Baltimore – (October 15, 2008)-Clinical Trials & Surveys Corp. (C-TASC), a clinical trials solutions company, announced today that it will assist the Food & Drug Administration (FDA) Centers for Quality Assurance and Biostatistics to develop new methods and procedures for evaluating all New Drug Applications (NDAs) submitted for FDA approval.
Under the $5.5 million base Indefinite Delivery Indefinite Quantity (IDIQ) contract, C-TASC will use components of its StudyCTMSTM study management software application to customize a solution for the FDA that will standardize how clinical trial data for new therapies will be presented and reviewed. C-TASC statisticians will also work with FDA staff to perform some of the data preparations and analyses for these reviews.
StudyCTMSTM is C-TASC’s proprietary Web-based data management solution that enables clinical trials managers to easily develop and manage clinical studies and deliver the accumulated data and metadata (labels, value labels, etc.) in an easy-to-read and FDA-acceptable format.
“C-TASC first developed StudyCTMSTM to allow our staff to manage our own clinical trial data more efficiently, and the benefits we experienced from its use were so significant we recognized an opportunity to influence others in the clinical trials industry,” said Bruce Thompson, president of C-TASC. “To now have the FDA implement elements of StudyCTMSTM to assess all New Drug Applications proves that our solution’s capabilities have the potential to evolve the industry standard processes for collecting, managing and presenting clinical data.”
About C-TASC
Based in Baltimore, Clinical Trials & Surveys Corporation (C-TASC) is a clinical trials solutions company that supports best practices to run safe and effective clinical trials, clinical cohort studies, case/control studies, clinical registries and laboratory studies. Founded in 1989, C-TASC provides clients with complete research management including medical and statistical study design, project management, performance monitoring and data quality control and analysis as well as support for study publication and presentations. C-TASC’s professional services group has a successful research history in cancer, cardiovascular disease, AIDS, pulmonary disease, Cystic Fibrosis, pharmaco-epidemiology and bio-repository services and coordination. For more information about C-TASC’s projects, products and services, please visit www.c-tasc.com <http://www.c-tasc.com/> .
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.